Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Transfer of Fresh Versus Frozen/Thawed Embryos in IVF Cycles Where GnRH Agonist is Utilized for Oocyte Maturation.

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2006 by HaEmek Medical Center, Israel.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier:
NCT00365027
First received: August 15, 2006
Last updated: NA
Last verified: August 2006
History: No changes posted

August 15, 2006
August 15, 2006
Not Provided
Not Provided
  • Implantation rate per transfer
  • Pregnancy rate per embryo transfer
  • Implantation rate per IVF cycle
  • Pregnancy rate per IVF cycle
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Transfer of Fresh Versus Frozen/Thawed Embryos in IVF Cycles Where GnRH Agonist is Utilized for Oocyte Maturation.
Not Provided

It has been suggested that in IVF cycles where GNRH agonist is utilized for final oocyte maturation in patients at risk of ovarian hyperstimulation, pregnancy rates are reduced. We hypothesize that the use of GNRH antagonist reduces pregnancy rates through an effect on the endometrium and not oocyte quality, therefore better results may be obtained by not returning these embryos in a fresh cycle but rather cryopreserving them and returning them to the uterus and a later stage.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Ovarian Hyperstimulation Syndrome
  • Infertility Drugs
  • Female
Procedure: Delayed embryo transfer
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Woman at risk of ovarian hyperstimulation syndrome in IVF cycles for whom GNRH agonist was utilized for final oocyte maturation

Exclusion Criteria:

  • Patient's refusal to participate
Female
18 Years and older
No
Contact: Ronit Beck Fruchter, Dr 972-4-6495565 beck_r@clalit.org.il
Not Provided
 
NCT00365027
5040706
Not Provided
Not Provided
HaEmek Medical Center, Israel
Not Provided
Study Chair: Eliezer Shalev HaE'mek medical center
HaEmek Medical Center, Israel
August 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP